Regulatory and pipeline: FDA drafts faster pathway for personalized gene therapies

The FDA published draft guidance describing a quicker approval pathway for certain individualized gene therapies, aiming to streamline development in rare-disease settings. The proposal drew attention from patient advocates who have argued for more predictable review timelines for personalized approaches.